158 related articles for article (PubMed ID: 15743504)
41. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
42. The spindle checkpoint: how do cells delay anaphase onset?
Sczaniecka MM; Hardwick KG
SEB Exp Biol Ser; 2008; 59():243-56. PubMed ID: 18368927
[TBL] [Abstract][Full Text] [Related]
43. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
44. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer.
Chakravarty G; Moroz K; Makridakis NM; Lloyd SA; Galvez SE; Canavello PR; Lacey MR; Agrawal K; Mondal D
Exp Biol Med (Maywood); 2011 Feb; 236(2):145-55. PubMed ID: 21321311
[TBL] [Abstract][Full Text] [Related]
46. Aurora kinase B expression in breast carcinoma: cell kinetic and genetic aspects.
Hegyi K; Egervári K; Sándor Z; Méhes G
Pathobiology; 2012; 79(6):314-22. PubMed ID: 22688343
[TBL] [Abstract][Full Text] [Related]
47. Chromosome separation and exit from mitosis in budding yeast: dependence on growth revealed by cAMP-mediated inhibition.
Anghileri P; Branduardi P; Sternieri F; Monti P; Visintin R; Bevilacqua A; Alberghina L; Martegani E; Baroni MD
Exp Cell Res; 1999 Aug; 250(2):510-23. PubMed ID: 10413604
[TBL] [Abstract][Full Text] [Related]
48. 2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells.
Bhati R; Gökmen-Polar Y; Sledge GW; Fan C; Nakshatri H; Ketelsen D; Borchers CH; Dial MJ; Patterson C; Klauber-DeMore N
Cancer Res; 2007 Jan; 67(2):702-8. PubMed ID: 17234781
[TBL] [Abstract][Full Text] [Related]
49. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.
Kim HS; Vassilopoulos A; Wang RH; Lahusen T; Xiao Z; Xu X; Li C; Veenstra TD; Li B; Yu H; Ji J; Wang XW; Park SH; Cha YI; Gius D; Deng CX
Cancer Cell; 2011 Oct; 20(4):487-99. PubMed ID: 22014574
[TBL] [Abstract][Full Text] [Related]
50. Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.
Talvinen K; Tuikkala J; Nevalainen O; Rantanen A; Hirsimäki P; Sundström J; Kronqvist P
Br J Cancer; 2008 Jul; 99(2):335-40. PubMed ID: 18594525
[TBL] [Abstract][Full Text] [Related]
51. Nuclear pore protein NUP88 activates anaphase-promoting complex to promote aneuploidy.
Naylor RM; Jeganathan KB; Cao X; van Deursen JM
J Clin Invest; 2016 Feb; 126(2):543-59. PubMed ID: 26731471
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas.
Loussouarn D; Campion L; Sagan C; Frenel JS; Dravet F; Classe JM; Pioud-Martigny R; Berton-Rigaud D; Bourbouloux E; Mosnier JF; Bataille FR; Campone M
Br J Cancer; 2008 Jun; 98(12):1993-8. PubMed ID: 18542065
[TBL] [Abstract][Full Text] [Related]
53. The Secret Life of the Inhibitor of Virus Replication.
Palukaitis P; Akbarimotlagh M; Baek E; Yoon JY
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560786
[TBL] [Abstract][Full Text] [Related]
54. CUEDC2: an emerging key player in inflammation and tumorigenesis.
Man J; Zhang X
Protein Cell; 2011 Sep; 2(9):699-703. PubMed ID: 21976060
[TBL] [Abstract][Full Text] [Related]
55. Securin promotes the identification of favourable outcome in invasive breast cancer.
Talvinen K; Karra H; Hurme S; Nykänen M; Nieminen A; Anttinen J; Kuopio T; Kronqvist P
Br J Cancer; 2009 Sep; 101(6):1005-10. PubMed ID: 19690544
[TBL] [Abstract][Full Text] [Related]
56. Phenotype-directed analysis of genotype in early-onset, familial breast cancers.
Price GR; Armes JE; Ramus SJ; Provenzano E; Kumar B; Cowie TF; Ciciulla J; Hutchins AM; Thomas M; Venter DJ
Pathology; 2006 Dec; 38(6):520-7. PubMed ID: 17393978
[TBL] [Abstract][Full Text] [Related]
57. Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
Yu VM; Marion CM; Austria TM; Yeh J; Schönthal AH; Dubeau L
Int J Cancer; 2012 Jun; 130(11):2495-504. PubMed ID: 21792894
[TBL] [Abstract][Full Text] [Related]
58. The importance of CDC27 in cancer: molecular pathology and clinical aspects.
Kazemi-Sefat GE; Keramatipour M; Talebi S; Kavousi K; Sajed R; Kazemi-Sefat NA; Mousavizadeh K
Cancer Cell Int; 2021 Mar; 21(1):160. PubMed ID: 33750395
[TBL] [Abstract][Full Text] [Related]
59. What is the Meaning of Anaphase-Promoting Complex 7 in Malignant Neoplasms?
Chang WY
Ann Coloproctol; 2017 Aug; 33(4):123-124. PubMed ID: 28932719
[No Abstract] [Full Text] [Related]
60. Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancer.
VanKlompenberg MK; Bedalov CO; Soto KF; Prosperi JR
BMC Cancer; 2016 Nov; 16(1):921. PubMed ID: 27894290
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
